Varicella Zoster Virus (live attenuated) Vaccine
Indications
Varicella Zoster Virus (live attenuated) Vaccine is used for:
Varicella-Zoster Virus Infection
Adult Dose
Subcuteneous
Varicella-Zoster Virus Infection
0.65 mL (entire content of vial ) injected SC into upper arm as single dose
Child Dose
Not indicated
Renal Dose
Administration
Contra Indications
A history of hypersensitivity to any component of the vaccine; individuals with blood dyscrasias, leukonia, lymphomas of any type, or other malignant neoplasma affecting the bone marrow or lymphatic systems; individuals receiving immunosuppressive therapy.
Precautions
Vaccination should be deferred to at least 5 months following blood or plasma transfusion, or administration of immunoglobulin or varicella-zoster immunoglobulin (VZIG).
Vaccination should be deferred in patients with a family history of congenital or hereditary immunodeficiency until the patient's own immune system has been evaluated.
Cases Requiring Careful Consideration Before Vaccination: The decision for vaccination is to be made carefully in the following categories, those having a history of seizures; those previously diagnosed with an immunodeficiency; those suffering from diseases accompanied by abnormal immune system function or those receiving immunosuppressive therapy; and those suspected of being allergic to any of the components.
Lactation: Unknown whether agent is excreted in breast milk; use with caution
Pregnancy-Lactation
Interactions
Concurrent use may interfere with the immune response to certain live vaccines.
Adverse Effects
Side effects of Varicella Zoster Virus (live attenuated) Vaccine :
>10%
Injection-site erythema,Pain or tenderness,Pruritus,Swelling,Warmth
1-10%
Diarrhea (2%),Fever (2%),Flulike syndrome (2%),Upper respiratory tract infection (2%),Headache (1%),Rhinitis (1%),Skin disorder (1%),Weakness (1%)
<1%
Arthralgia,Hypersensitivity,Injection-site reactions
Mechanism of Action
Conveys active immunity by stimulating production of endogenously produced antibodies